• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Scanis signs on Trex as distributor

Article

Scanis took a major step forward this month in laying the groundwork for commercial launch of its Mammex TR computer-aided detection workstation. The Foster City, CA, company has signed a letter of intent to set up a worldwide distribution deal for

Scanis took a major step forward this month in laying the groundwork for commercial launch of its Mammex TR computer-aided detection workstation. The Foster City, CA, company has signed a letter of intent to set up a worldwide distribution deal for Mammex TR with mammography heavyweight Trex Medical of Danbury, CT.

The agreement calls for Trex to receive exclusive worldwide sales and marketing rights to the workstation for five years. Mammex TR could be used either with Trex's full-field digital mammography system or with digitized mammography film to flag suspicious areas on an image for a radiologist's attention. Mammex TR will be shown as a work-in-progress at this month's Radiological Society of North America meeting.

Recent Videos
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Related Content
© 2025 MJH Life Sciences

All rights reserved.